Summary
46 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 325 USD is left as net profit.
- It could repay all its net debt from 0.6 years of operating profit.
What to watch
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 10.7 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 4.2 USD
- Research and development 162 USD
- Sales and administration 123 USD
- Taxes and other -514 USD
- Net profit 325 USD
Net profit, industry median (Biotechnology) -6.9 USD
Out of every 100 USD of revenue, 325 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 5
- Sell 2
Today's price within the analysts' price targets
The average target of $27.5 is 46% above today's price. 63% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.